FDA grants orphan drug designation for neuroblastoma vaccine

The U.S. Food and Drug Administration granted orphan drug designation for a neuroblastoma vaccine from MabVax Therapeutics, providing development incentive with market exclusivity of the novel treatment for children with this deadly childhood cancer. The vaccine harnesses the power of a child's own immune system to recognize and destroy cancer cells that express the two antigens most commonly found on the surface of neuroblastoma cells-GD2 and GD3, potentially promoting long-term remissions.

http://ift.tt/Zqswi0